Drug profile
The FDA adverse-event record for Semintra Telmisartan 4 Mg/Ml
124 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Semintra Telmisartan 4 Mg/Ml. See the species affected, top reactions, and outcomes below.
- 124
- adverse-event reports
- 12.1%
- death-coded share
- Cat
- most-reported species
- 24
- Vomiting - top reaction
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Semintra Telmisartan 4 Mg/Ml Adverse Event Insights
124 reports name Semintra Telmisartan 4 Mg/Ml; 15 recorded a death outcome (12.1% of reported events, not a population-level mortality rate). Active ingredient: Semintra Telmisartan 4 Mg/Ml. Administration route: Oral.
By species: Cat (124 reports). By breed: Domestic Shorthair (98), Siamese (13), Himalayan (7).
Leading clinical signs: Vomiting (24), Weight loss (14), Death by euthanasia (14), Decreased appetite (12). Outcome, 124 coded reports: Outcome Unknown leads at 48.4%.
Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.